Science Corporation, a medical tech startup founded by former Neuralink president Max Hodak, secured $400 million in Series D funding to further develop its implantable brain chip technology, raising its valuation to $3.5 billion.
- Raised $400 million Series D, valuing company at $3.5 billion
- PRIMA device helps restore vision in macular degeneration patients
- Plans underway for US FDA approval and neurological disorder trials
What happened
Science Corporation announced a $400 million Series D funding round, which pushed its valuation to $3.5 billion. This round included investments from prominent firms such as Khosla Ventures, Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. Founded in 2021 by Max Hodak, the company focuses on innovative brain-computer interface technology.
Why it matters
Science Corporation’s advancements mark a significant step forward in neurotechnology, combining cultured neurons with silicon to create bio-hybrid sensors capable of direct brain interaction. This approach has the potential to revolutionize treatment for a variety of neurological impairments beyond vision restoration.
Securing substantial funding and regulatory traction signals growing investor confidence in brain-machine interface innovations. Furthermore, the company's work could open new therapeutic avenues for diseases such as Parkinson’s, addressing conditions with limited treatment options today.
What to watch next
The startup is also preparing for initial human trials of its next-generation brain interface device in collaboration with neurosurgery experts like Professor Murat Günel at Yale. These trials will explore applications extending to neurological conditions such as Parkinson’s disease, which could significantly expand the company’s impact in medical technology.